Clinical setbacks for toll-like receptor 9 agonists in cancer.
Charlie
C
Schmidt
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends*; D017277:Drug Approval; D004345:Drug Industry / Q000639:trends*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D051217:Toll-Like Receptor 9 / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; C495371:TLR9 protein, human; D051217:Toll-Like Receptor 9